- Home
- NXTC vs EDUC Comparison
NXTC vs EDUC Comparison
Compare NXTC & EDUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- EDUC
- Stock Information
- Founded
- NXTC 2015
- EDUC 1965
- Country
- NXTC United States
- EDUC United States
- Employees
- NXTC N/A
- EDUC N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- EDUC Consumer Specialties
- Sector
- NXTC Health Care
- EDUC Consumer Discretionary
- Exchange
- NXTC Nasdaq
- EDUC Nasdaq
- Market Cap
- NXTC 12.8M
- EDUC 11.4M
- IPO Year
- NXTC 2019
- EDUC N/A
- Fundamental
- Price
- NXTC $4.85
- EDUC $1.10
- Analyst Decision
- NXTC Strong Buy
- EDUC
- Analyst Count
- NXTC 2
- EDUC 0
- Target Price
- NXTC $25.50
- EDUC N/A
- AVG Volume (30 Days)
- NXTC 18.5K
- EDUC 314.0K
- Earning Date
- NXTC 11-06-2025
- EDUC 10-09-2025
- Dividend Yield
- NXTC N/A
- EDUC N/A
- EPS Growth
- NXTC N/A
- EDUC N/A
- EPS
- NXTC N/A
- EDUC N/A
- Revenue
- NXTC N/A
- EDUC $31,304,000.00
- Revenue This Year
- NXTC N/A
- EDUC N/A
- Revenue Next Year
- NXTC N/A
- EDUC N/A
- P/E Ratio
- NXTC N/A
- EDUC N/A
- Revenue Growth
- NXTC N/A
- EDUC N/A
- 52 Week Low
- NXTC $2.69
- EDUC $0.92
- 52 Week High
- NXTC $19.20
- EDUC $2.49
- Technical
- Relative Strength Index (RSI)
- NXTC 41.16
- EDUC 41.09
- Support Level
- NXTC $4.83
- EDUC $1.08
- Resistance Level
- NXTC $5.15
- EDUC $1.18
- Average True Range (ATR)
- NXTC 0.23
- EDUC 0.08
- MACD
- NXTC -0.02
- EDUC 0.01
- Stochastic Oscillator
- NXTC 7.14
- EDUC 28.13
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.